Jones Trading has initiated coverage on CG Oncology Inc (CGON) with a Buy rating, marking its first assessment of the biotechnology firm. This rating follows the company's development of a bladder-sparing therapeutic aimed at treating non-muscle invasive bladder cancer (NMIBC).
Based in Irvine, California, CG Oncology is focused on advancing its product candidate, cretostimogene grenadenorepvec (cretostimogene), which is currently in clinical trials. The firm's BOND-003 trial is in Phase III, evaluating the safety and efficacy of cretostimogene as a monotherapy for patients with high-risk, BCG-unresponsive NMIBC, while CORE-001 is a Phase II trial assessing the same candidate in a different patient cohort. Additionally, the PIVOT-006 trial is underway to investigate the use of cretostimogene in patients with intermediate-risk NMIBC following transurethral resection of bladder tumors (TURBT).
As of September 7, 2025, CG Oncology's stock is priced at $41.36, contributing to a market capitalization of $3.3 billion. The company has reported a trailing twelve-month EPS of -1.76. Upcoming earnings are expected on August 6, 2026, with an estimated EPS of -0.75 and no revenue anticipated.
Analyst ratings like this one provide insights based on extensive research and financial modeling. However, they reflect professional opinions that can change as new information emerges. Investors should consider a range of factors, including company fundamentals and market conditions, when making decisions. Analyst views are best seen as one of many inputs in the investment process.
The recent consensus among analysts reflects a positive outlook, with 4 Strong Buy ratings, 14 Buy ratings, and 1 Hold rating, resulting in a consensus rating of Buy as of November 1, 2025.